Bagust A[au] - Search Results

Year	Number of Results
1988	1
1989	2
1990	1
1991	1
1992	1
1993	1
1996	1
1997	2
1999	3
2000	2
2001	4
2002	3
2003	5
2004	4
2005	3
2006	6
2007	5
2008	3
2009	8
2010	9
2011	3
2013	5
2014	2
2015	7
2017	1
2018	3
2019	2
2020	1
2024	0

1

Rituximab for the treatment of rheumatoid arthritis.

Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R. Bagust A, et al. Health Technol Assess. 2009 Sep;13 Suppl 2:23-9. doi: 10.3310/hta13suppl2/04. Health Technol Assess. 2009. PMID: 19804686 Free article. Review.

2

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M. Greenhalgh J, et al. Among authors: bagust a. Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Health Technol Assess. 2010. PMID: 20507801 Free article. Review.

3

Accounting for noncompliance in pharmacoeconomic evaluations.

Hughes DA, Bagust A, Haycox A, Walley T. Hughes DA, et al. Among authors: bagust a. Pharmacoeconomics. 2001;19(12):1185-97. doi: 10.2165/00019053-200119120-00001. Pharmacoeconomics. 2001. PMID: 11772154 Review.

4

Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.

Greenhalgh J, Bagust A, Boland A, Oyee J, Trevor N, Beale S, Dundar Y, Hockenhull J, Proudlove C, O'Reilly S. Greenhalgh J, et al. Among authors: bagust a. Pharmacoeconomics. 2015 Feb;33(2):137-48. doi: 10.1007/s40273-014-0214-2. Pharmacoeconomics. 2015. PMID: 25213036 Review.

5

Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.

Fleeman N, Bagust A, Beale S, Boland A, Dickson R, Dwan K, Richardson M, Dundar Y, Davis H, Banks L. Fleeman N, et al. Among authors: bagust a. Pharmacoeconomics. 2015 Sep;33(9):893-904. doi: 10.1007/s40273-015-0276-9. Pharmacoeconomics. 2015. PMID: 25906420 Review.

6

Coronary artery stents: a rapid systematic review and economic evaluation.

Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T. Hill R, et al. Among authors: bagust a. Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242. doi: 10.3310/hta8350. Health Technol Assess. 2004. PMID: 15361315 Free article. Review.

7

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Fleeman N, Bagust A, Duarte R, Richardson M, Nevitt S, Boland A, Kotas E, McEntee J, Thorp N. Fleeman N, et al. Among authors: bagust a. Pharmacoecon Open. 2019 Sep;3(3):293-302. doi: 10.1007/s41669-018-0114-z. Pharmacoecon Open. 2019. PMID: 30742256 Free PMC article. Review.

8

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.

Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P. Greenhalgh J, et al. Among authors: bagust a. Pharmacoeconomics. 2013 May;31(5):403-13. doi: 10.1007/s40273-013-0043-8. Pharmacoeconomics. 2013. PMID: 23576017 Free PMC article. Review.

9

A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.

Pilkington G, Boland A, Brown T, Oyee J, Bagust A, Dickson R. Pilkington G, et al. Among authors: bagust a. Thorax. 2015 Apr;70(4):359-67. doi: 10.1136/thoraxjnl-2014-205914. Epub 2015 Feb 6. Thorax. 2015. PMID: 25661113 Review.

10

Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.

Fleeman N, Bagust A, Beale S, Dwan K, Dickson R, Proudlove C, Dundar Y. Fleeman N, et al. Among authors: bagust a. Pharmacoeconomics. 2015 Jan;33(1):13-23. doi: 10.1007/s40273-014-0206-2. Pharmacoeconomics. 2015. PMID: 25138171 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

86 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year